Nature Med. 5, 275– 279 (1999).
On page 278, the original Fig. 3, ommitted four gap symbols and two amino-acid changes. The correct figure is shown.
The online version of the original article can be found at 10.1038/6488
About this article
Cite this article
Kadkol, S., Brody, J., Pevsner, J. et al. Correction to “Modulation of oncogenic potential by alternative gene use in human prostate cancer”. Nat Med 5, 1087 (1999). https://doi.org/10.1038/12530
Overexpression of the pp32r1 (ANP32C) oncogene or its functional mutant pp32r1Y140H confers enhanced resistance to FTY720 (Finguimod)
Cancer Biology & Therapy (2014)
Cracking the ANP32 whips: Important functions, unequal requirement, and hints at disease implications
High Altitude Medicine & Biology (2014)
Dysregulation of cell cycle control caused by overexpression of the oncogene pp32r1 (ANP32C) and the Tyr>His mutant pp32r1Y140H
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research (2013)
Clinical & Experimental Metastasis (2010)